NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Sun Pharmaceutical Industries Ltd.’s Q2 FY25 earnings were above estimates on account of higher gross margin and lower R&D costs.
The company lowered its research and development expense guidance from 8-10% to 7-8% of sales, for FY25. India business is expected to grow inline or above the IPM.
We upgrade our FY25E/FY26E earnings per share estimate by 2.0%/4.1% assuming lower R&D and depreciation cost. Rolling over to FY27 we maintain ‘Reduce’ rating with a revised target price of Rs 1,921 at 30 times FY27E P/E.
Click on the attachment to read the full report:
Also Read: Sun Pharma Q2 Results Review - India Branded Generic Growth Surprises; Upgrade To 'Buy': Systematix
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
Orchid Pharma Q2 Results Review - Inline Revenue, Gross Margins Come Higher: Systematix
Nov 12, 2024
Alembic Pharma Q2 Results Review - Miss On Operating Performance: Dolat Capital
Nov 08, 2024
Sun Pharma’s Leqselvi Launch Blocked By US Court
Nov 02, 2024
Sun Pharma, BPCL, Federal Bank, Macrotech, CDSL, Syrma, Cholamandalam And More Q2 Review: HDFC Securities
Oct 29, 2024
POPULAR